Navigation Links
More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy
Date:4/7/2008

Less Than 20 Percent of Patients Diagnosed with the Disease Receive Pharmacotherapy Within a Year of Their Diagnosis, According to a New Report

From Decision Resources

WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's Flomax, also marketed as Astellas's Harnal in Japan, is the physician's drug of choice for newly diagnosed benign prostatic hyperplasia patients. Garnering more patient share than any other alpha blocker in first- and second-line therapy for benign prostatic hyperplasia, Flomax holds a 55.2 percent first-line patient share, compared with 12.4 percent for Sanofi-Aventis's Uroxatral, 4.8 percent for doxazosin (Pfizer's Cardura/Cardura XL, generics), and 4.3 percent for terazosin (Abbott's Hytrin, generics).

"Flomax stands out among alpha blockers thanks to its lower propensity to induce orthostatic hypotension, despite evidence of a high incidence of retrograde ejaculation and higher cost relative to generic agents in this class", said Nathan Calloway, analyst at Decision Resources. "However, rather than calling attention to Flomax's side-effect/safety profile, the highest proportion of urologists we surveyed (83 percent) rank familiarity with the drug as an important reason to choose Flomax over Uroxatral, whereas the largest percentage of primary care physicians (66 percent) believe that Flomax's reimbursement and formulary position is a key advantage over Uroxatral's."

The report entitled Treatment Algorithms in Benign Prostatic Hyperplasia also finds that slightly less than one-fifth (18.9 percent) of newly diagnosed benign prostatic hyperplasia patients receive pharmacological treatment within one year of their initial diagnosis. Primary care physicians and urologists surveyed suggest that patient reluctance to take drugs that are associated with sid
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
5. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
10. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
11. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the ... Annual Meeting of Stockholders on May 4, 2015 (the ... the Annual Meeting represents a change of more than ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On ... law H.R. 83, the Omnibus and Continuing Resolution ... time, made hydrocephalus a condition eligible to receive ... (CDMRP) administered by the Department of Defense (DoD). ... its allies on Capitol Hill, is celebrating this ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... today announced,that researchers will present eight abstracts ... Meeting of the American Thoracic Society, from ... Presentations are designed to showcase,MedImmune,s biologics capabilities., ... solutions that may one,day help patients struggling ...
... Novasys Medical, Inc., a,developer of innovative therapies ... $49.5 million in Series D preferred stock financing. ... Partners and Skyline,Ventures also participating as new investors. ... Capital Management, Alloy,Ventures, Delphi Ventures, GBS Venture Partners, ...
... Revenues Increase Over 29% From Previous Quarter, ... (OTC:,SPOM), a leading developer of biosensor and microprocessor ... first quarter results for,the period ended March 31, ... US$1,079,000, a 29% increase over,fourth quarter 2007 gross ...
Cached Biology Technology:Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society 2Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women 2SPO Medical Reports First Quarter 2008 Results 2SPO Medical Reports First Quarter 2008 Results 3
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... additional brush strokes to the revolutionary new image now emerging ... cord. Their report, which suggests a key role for astrocytes ... online in ACS, Journal of Proteome Research , a ... point out that nearly everyone viewed astrocytes the most ...
... from The University of Alabama used worms to reel in ... of cellular mechanisms that may be exploited to treat epilepsy. ... ( http://www.genetics.org ), the researchers explain how the transparent ... switches" that control the transport of a molecule (gamma-aminobutyric acid ...
... taint" smell in the meat and allows them to contain ... different. Now, for the first time, a scientific team has ... The main conclusion of the study, that forms part of ... by the livestock farmers, without anaesthetic and in some cases, ...
Cached Biology News:More than fish bait: Worms unlock secrets to new epilepsy treatments 277 percent of European pigs are castrated without anesthetic 2
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
PMA (YPMA-1)...
Biology Products: